^
    over1year
    Report of oleclumab (anti-CD73) plus osimertinib in #EGFR NSCLC @JTOonline. CD73 often overexpressed in EGFR mutant NSCLC. Explored post 1G/2G TKI, T790M negative, osi naive. At dose level 2, RR 12% with mPFS 7.4m, mOS 25m. https://t.co/we5zEtPi4r (@StephenVLiu)
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR overexpression • CD73 overexpression • EGFR T790M negative • CD73 expression
    |
    Tagrisso (osimertinib) • oleclumab (MEDI9447)
    almost2years
    Hypothesis-generating: Addition of afatanib to patients c/ EGFR over-expressing met gastric cancer should be explored. Addition of IO to chemo (or in place of chemo) for periop Rx of resectable gastric cancer should be explored, esp among pts c/ MSI-H/dMMR/hPDL1CPS tumors. (@tpjmd)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • EGFR expression • EGFR overexpression • MET overexpression • MET expression
    almost3years
    Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells - Interesting and productive old collaboration (@AndresFCardonaZ)
    EGFR (Epidermal growth factor receptor) • FGFR1 (Fibroblast growth factor receptor 1)
    |
    EGFR overexpression • FGFR1 overexpression
    over3years
    First, #VEGF is highly expressed in #EGFR mutant cell lines (HCC827, H3255) and TKI therapy drops VEGF mRNA while in resistant setting (H1975 with T790M), erlotinib has no impact on high VEGF levels. In EGFRmt NSCLC, VEGF secretion is EGFR dependent. (@StephenVLiu)
    Preclinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR expression • EGFR overexpression • EGFR H1975
    |
    erlotinib